p16/INK4a gene alterations have been associated with tumor progression in lymphoid malignancies. However, their significance in mucosa-associated lymphoid tissue (MALT) lymphoma is unclear. We investigated p16 gene methylation and mutation in a large series of untreated cases of pulmonary MALT lymphoma and diffuse large B-cell lymphoma (DLBL), and correlated p16 gene alterations with a MALT lymphoma-specific API2-MALT1 fusion and the clinicopathologic features of MALT lymphoma. The API2-MALT1 fusion was detected by multiplex reverse transcription polymerase chain reaction in 25/60 (42%) cases of MALT lymphoma, but none of 11 DLBLs. Methylation-sensitive single-strand conformation analysis showed that p16 gene methylation was frequently detected in 36/60 (60%) cases of MALT lymphoma. The gene was similarly methylated in DLBL cases (6/11, 55%). A p16 gene mutation was found in one (p16 gene-methylation) of 44 MALT lymphomas and in none of six diffuse large B-cell lymphomas. Statistical analysis showed that the p16 gene methylation status did not correlate with API2-MALT1 fusion or any of the clinicopathologic factors including serum LDH, clinical stage, and increased large cells. These findings suggest that p16 methylation is not associated with tumor progression, but may be an early event in MALT lymphomagenesis that might be maintained through the progression of the tumor.
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) runs an indolent clinical course, involves extranodal sites, and exhibits a wide spectrum of histologic features consisting of centrocyte-like cells, lymphoepithelial lesions, and follicular colonization. Pre-existing chronic inflammation, for example, Helicobacter pylori gastritis, Hashimoto's thyroiditis, or Sjogren's syndrome, is considered to be important in the development of MALT lymphoma. Progression to diffuse large B-cell lymphoma (DLBL) may occur in some cases. 1 An API2-MALT1 gene fusion was cloned from a recurring chromosomal translocation of t(11;18)(q21;q21). 2, 3 Since this fusion is often the sole gene abnormality found in MALT lymphoma and has not been found in other types of lymphoma, API2-MALT1 fusion has been considered as a specific MALT lymphoma-causing alteration. [4] [5] [6] API2 is a member of the IAP (inhibitor of apoptosis) gene family, and is essential for the suppression of apoptosis. 7 MALT1 is identical to a novel caspase-like protein termed paracaspase, 8 although its biologic function remains unclear. It has been suggested that API2-MALT1 fusion transcripts lead to an increased inhibition of apoptosis and thereby help MALT lymphoma cells to survive. 9 Cell cycle progression is regulated by complexes formed between cyclins and cyclin-dependent kinases (CDKs). CDK4 and CDK6 bind to D-type cyclins in the G1 phase of the cell cycle and control G1/S transition through the phosphorylation of retinoblastoma protein. The activity of cyclinD-CDK4/6 complexes is subjected to additional levels of regulation, including the association with CDK inhibitors. 10 The p16/INK4a gene, mapped to 9q21, encodes for nuclear protein that can block cell cycle progression by effectively inhibiting the kinase activity of CDK4/6, thereby exerting a negative control on cell proliferation. p16 gene has been considered as a tumor-suppressor gene, and among CDK inhibitors, only p16 gene is frequently silenced in a variety of tumors by epigenetic or genetic abnormalities including promoter CpG methylation and less frequently, allelic loss and gene mutation. 10, 11 In lymphoid malignancies, p16 gene silencing, mainly induced by gene methylation, is frequently found in Hodgkin and non-Hodgkin lymphomas, [12] [13] [14] and has been associated with tumor progression. [15] [16] [17] [18] [19] However, it has also been suggested that the methylation of this gene is one of the early events in the development of lymphoid malignancies. [20] [21] [22] MALT lymphoma constitutes more than 80% of all primary lung lymphomas. 23 It should be noted that the involvement of API2-MALT1 fusion is particularly high (up to half of all cases) in pulmonary MALT lymphoma compared with MALT lymphomas at other sites, 24 and may define a distinctive clinicopathologic subgroup of pulmonary MALT lymphomas. 25 Therefore, pulmonary MALT lymphoma is a good model for study of lymphomagenesis. Like other lymphoid malignancies, the p16 gene silencing has been associated with tumor progression in MALT lymphoma. 16 However, recent studies showed frequent p16 gene methylation in gastric MALT lymphomas at diagnosis, suggesting that it might be an early event. 26, 27 To clarify lymphomagenetic and clinicopathologic significances of p16 gene alterations, we investigated the promoter hypermethylation and sequence mutation of this gene in a large series of pulmonary MALT lymphomas, and correlated these changes with API2-MALT1 fusion.
Materials and methods

Case Selection
Specimens of MALT lymphoma (n ¼ 60) and diffuse large B-cell lymphoma (n ¼ 11) obtained at the initial presentation of the patients were fixed in formalin, and embedded in paraffin. The diagnosis of MALT lymphoma was made according to the criteria of the World Health Organization classification. 1 All of the cases were within the morphological boundaries of MALT lymphoma, and exhibited the following immunophenotype: CD20 þ , CD79a þ , CD3À, CD45ROÀ, CD5À, CD10À, CD23À, and cyclin D1À. A precise microscopic observation revealed that 46 of 60 cases were 'typical' in histology. 1, 25 However, seven cases showed an increased number of large cells (5%olarge cells o10%, without solid or sheet-like proliferations), and seven cases exhibited marked plasmacytoid differentiation (plasmacytoid tumor cells 490%). The mean age of MALT lymphoma patients was 62.1 years with a range of 31-94 years. The male/female ratio was 22/38. The mean age of DLBL patients was 61 years with a range of 37-84 years. The male/ female ratio was 7/4. Some of the tumors in this series were included in our previous study. 25 Extraction of Genomic DNA and Total RNA On examination of tissue sections under a dissecting microscope, selected areas were retrieved using a serial H&E section as a guide. Genomic DNA and total RNA were extracted in digestion buffer containing proteinase K as previously described. 25, 28 For all cases included in this study, monoclonality was confirmed by a polymerase chain reaction (PCR) clonality assay of the immunoglobulin heavy chain gene and/or immunohistochemistry for immunoglobulin light chains as previously described. 25 We also confirmed that all cases had a sufficient quality of RNA by reverse transcription (RT)-PCR for betaactin mRNA (190 base). 28 As normal controls, 12 lung and 14 lymph node specimens were used and these were obtained from carcinoma patients during surgery.
Multiplex RT-PCR for the API2-MALT1 Fusion Transcript
The API2-MALT1 fusion transcript was detected using archival paraffin sections according to the method we previously reported. 28 All eight variant fusion transcripts that have been reported to date can be detected with this assay (Figure 1a ; accession number L49432 for API2 and accession number AF130356 for MALT1). Briefly, total RNA was subjected to first-round multiplex one-tube RT-PCR, then to second-round nested multiplex PCRs (three in parallel: second PCR-A, second PCR-B, and second PCR-C). This RT-PCR assay using paraffin tissues is highly efficient and has 94% of the sensitivity and 100% of the specificity obtained with RT-PCR using frozen materials. 25 
DNA Bisulfite Modification and Methylation-Specific Single-Strand Conformation Analysis (MS-SSCA)
Genomic DNA extracted from lymphoma samples and a Raji lymphoma cell line (methylation-positive control) were examined for p16 gene methylation by MS-SSCA. 29 In brief, DNA was first heated at 981C for 10 min, and then for another 10 min at 371C with the addition of freshly prepared 3 N NaOH. After addition of 10 nmol/l hydroquinone and 4.8 mol/l sodium bisulfite, the mixture was incubated at 551C overnight. DNA modification was completed by adding 0.2 mol/l NaOH/90% ethanol. A 194 bp fragment of the p16 gene promoter was amplified by p16/INK4a in pulmonary lymphoma H Takino et al PCR using the following primers specific to the modified sequences: 5 0 -GGGGGAGATTTAATTTGG-3 0 and 5 0 -CAACCCCTCCTCTTTCTT-3 0 . After denaturation, the PCR samples were immediately electrophoresed on a 30% MDE gel (Cambrex Bio Science Rockland, Rockland, ME, USA) with a constant voltage of 10 V/cm for 4 h at 201C. Gels were then stained with a SYBR Green I (Molecular Probes, Eugene, OR, USA), and bands were visualized with UV light.
Mutation Analysis of the p16 Gene by PCR-Single-Strand Conformation Polymorphism (SSCP) PCR amplification of the p16 gene was performed using a primer pair for exon 1 (GGGCGGCGGGGAG CAGC and GCTGCAGACCCTCTACCCAC) and two primer pairs for exon 2 (5 0 -ACCCTGGCTCTGAC CATTCTGT-3 0 and 5 0 -GGCATCGCGCACGTCCAGC-3 0 and 5 0 -GGGCTTCCTGGACACGCTGGT-3 0 and 5 0 -GGAAGCTCTCAGGGTACAAATTCTCA-3 0 ). 30 After denaturation, the PCR products were electrophoresed and separated using a GeneGel Exel 12.5/24 Kit (GenePhor System, Amersham Biosciences, Piscataway, NJ, USA) at two different temperatures, 151C and 51C, and the gels were subjected to silver staining. Mutational bands were excised from the gels and reamplified using the same PCR primers.
The amplified DNA was directly sequenced by means of cycle sequencing with dye-labeled terminators (BigDye Terminators, Applied Biosystems, Foster City, CA, USA) and analyzed on an automated DNA sequencer.
Statistical Analysis
Statistical evaluation of data from two groups was performed using Fischer's exact test and Student's t-test. All analyses were two-tailed. A probability value of Po0.05 for each test was regarded as statistically significant.
Results
API2-MALT1 Fusion Transcript
The multiplex RT-PCR detected API2-MALT1 fusion in 25/60 (42%) cases of pulmonary MALT lymphoma. The bands varied in size depending on the breakpoints and primer sets used (Figure 1 ). The API2 breakpoints were restricted to 1446 (accession number. L49432) in all cases with one exception which had a breakpoint at 1701. In contrast, the MALT1 breakpoint (accession number. L49432) varied with nine cases at 814, 10 cases at 1123, and six cases at 1150. API2-MALT1 fusion transcript was negative for MALT lymphomas with increased large cells (0/7 cases) and DLBLs (0/11).
p16 Gene Methylation Analysis by MS-SSCA
The p16 gene methylation was detected in 36/60 (60%) cases of MALT lymphoma: 32/53 (60%) and 4/7 (57%) cases of MALT lymphomas without and with an increased component of large cells, respectively ( Figure 2 ). The gene methylation was detected in 6/11 (55%) cases of DLBL. Statistically significant difference was not obtained between any two of the above groups. p16 gene methylation was detected in none of 12 normal lung tissues or 14 normal lymph node specimens. The p16 whole coding region was amplified in 44 cases of MALT lymphoma and eight cases of DLBL. One MALT lymphoma case (2%) showed a nucleotide substitution of G to A at codon 135 that changed GGG (glycine) to GAG (glutamic acid) (Figure 3 ). This case showed 'typical' MALT lymphoma histology and p16 gene methylation by MS-SSCA. None of the DLBL cases possessed p16 gene mutation.
Correlation of p16 Gene Methylation with Clinicopathologic Factors and API2-MALT1 Fusion
Available clinicopathologic factors included age, sex, chief complaints, autoimmune disease, serum LDH, clinical stage, B-symptoms, 'typical' histology, increased large cells, and marked plasmacytoid differentiation. p16 gene methylation correlated with none of these factors, nor did it correlate with API2-MALT1 fusion status (Table 1) .
Discussion
p16/INK4a gene methylation was detected in diagnostic specimens of more than half of the cases of not only MALT lymphoma but also MALT lymphoma with increased large cells and DLBL. The MS-SSCA used in this study is a rapid and specific procedure for detecting gene methylation, especially in paraffin-embedded tissues, and gives fewer false-positive results. 29 The influence of p16 gene methylation on background non-neoplastic cells is considered to be minimal because no methylation was detected in normal pulmonary tissues in the present and previous studies. 31 p16 gene mutation was found in one MALT lymphoma case, which involved methylation of the p16 gene. Consequently, gene methylation was a major occurrence among p16 gene alterations in our study, which is in accord with previous reports. [10] [11] [12] [13] [14] [15] [16] Gene deletion is another means of p16 gene silencing, but has been rare in MALT lymphomas. 32, 33 We attempted to detect p16 gene deletions using seven microsatellite markers, 16, 34 however, most of the cases were not amplifiable or informative. We found no evidence of p16 deletion in eight cases (six of MALT lymphoma and two of DLBL) that were suitable for evaluation (unpublished data).
The most important finding of our study is that p16 gene was frequently methylated in pulmonary MALT lymphomas (60% of the cases) at diagnosis. It was methylated with similar frequencies in MALT lymphomas with increased large cells (57%) and DLBLs (55%), and its gene methylation did not correlate with any of the clinical factors such as serum LDH, stage, and B-symptoms. p16 gene methylation has been considered to be a molecular event associated with the progression of MALT lymphoma to its high-grade counterpart. [15] [16] [17] [18] [19] However, our findings suggest that p16 gene methylation is not associated with the tumor progression but rather may contribute to the 35, 36 and by the frequent p16 gene methylation found in monoclonal gammopathy of undetermined significance, in the plaque phase of mycosis fungoides, and in other premalignant lesions. [20] [21] [22] 37 Several MALT lymphoma-specific or -associated gene alterations have been reported, such as translocations between the immunoglobulin heavy chain gene and BCL10 gene or MALT1 gene, trisomy 3, and trisomy 18, as well as API2-MALT1 fusion. 38 These seem to be mutually exclusive, and constitute up to 80% of the pulmonary MALT lymphoma cases. 38 A recent study of an API2-MALT1 transgenic mouse model showed that the expression of the fusion protein did not induce spontaneous development of MALT lymphomas, 39 suggesting that the fusion gene alone would not be sufficient for MALT lymphoma development. This would be also the case for other gene alterations. In this study, while p16 gene methylation was not directly associated with API2-MALT1 fusion, we speculate that it is important as one of the early events of MALT lymphomagenesis and plays a role in tumor development in cooperation with several MALT lymphoma-specific or -associated gene alterations. To date, several studies have shown that methylation-associated silencing of tumor suppressor genes is one of the cancer-predisposing hits described in Knudson's two hit theory. 11 Unlike genetic alterations, changes in DNA methylation are potentially reversible. This possibility has attracted considerable attention from a therapeutics standpoint. Nucleoside-analogue inhibitors of DNA methyltransferases, such as 5-aza-2 0 -deoxycytidine, are able to demethylate DNA and restore silenced gene expression. 40, 41 Recently, some non-nucleoside inhibitors of DNA methyltransferases have also been reported as promising candidate agents for future cancer therapies based on epigenetics, including procainamide and procaine. 42 The clinical and therapeutic significance of these agents in pulmonary MALT lymphoma should be investigated.
